Flagship Ventures Fund Iv-rx, L.p. - Net Worth and Insider Trading
Flagship Ventures Fund Iv-rx, L.p. Net Worth
The estimated net worth of Flagship Ventures Fund Iv-rx, L.p. is at least $1 Million dollars as of 2024-11-13. Flagship Ventures Fund Iv-rx, L.p. is the 10% Owner of Syros Pharmaceuticals Inc and owns about 480,666 shares of Syros Pharmaceuticals Inc (SYRS) stock worth over $1 Million. Details can be seen in Flagship Ventures Fund Iv-rx, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Flagship Ventures Fund Iv-rx, L.p. has not made any transactions after 2016-07-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Flagship Ventures Fund Iv-rx, L.p.
Flagship Ventures Fund Iv-rx, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Flagship Ventures Fund Iv-rx, L.p. owns 9 companies in total, including Moderna Inc (MRNA) , Evelo Biosciences Inc (EVLO) , and Axcella Health Inc (AXLA) among others .
Insider Ownership Summary of Flagship Ventures Fund Iv-rx, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MRNA | Moderna Inc | 2018-12-07 | 10 percent owner |
| EVLO | Evelo Biosciences Inc | 2018-05-08 | 10 percent owner |
| AXLA | Axcella Health Inc | 2020-05-18 | 10 percent owner |
 | | 2018-07-17 | 10 percent owner |
| | 2017-08-17 | 10 percent owner |
| | 2016-09-06 | 10 percent owner |
| | 2016-08-11 | 10 percent owner |
| | 2020-11-23 | 10 percent owner |
| | 2016-09-06 | 10 percent owner |
Flagship Ventures Fund Iv-rx, L.p. Latest Holdings Summary
Flagship Ventures Fund Iv-rx, L.p. currently owns a total of 1 stock. Flagship Ventures Fund Iv-rx, L.p. owns 480,666 shares of Syros Pharmaceuticals Inc (SYRS) as of July 6, 2016, with a value of $1 Million.
Latest Holdings of Flagship Ventures Fund Iv-rx, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2016-07-06 | 480,666 | 2.73 | 1,312,218 |
Holding Weightings of Flagship Ventures Fund Iv-rx, L.p.
Flagship Ventures Fund Iv-rx, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Flagship Ventures Fund Iv-rx, L.p. has made a total of 0 transactions in Syros Pharmaceuticals Inc (SYRS) over the past 5 years. The most-recent trade in Syros Pharmaceuticals Inc is the acquisition of 40,000 shares on July 6, 2016, which cost Flagship Ventures Fund Iv-rx, L.p. around $5 Million.
Insider Trading History of Flagship Ventures Fund Iv-rx, L.p.
- 1
Flagship Ventures Fund Iv-rx, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Flagship Ventures Fund Iv-rx, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Flagship Ventures Fund Iv-rx, L.p. is -20.83%. GuruFocus also compares Flagship Ventures Fund Iv-rx, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Flagship Ventures Fund Iv-rx, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Flagship Ventures Fund Iv-rx, L.p.'s insider trading performs compared to the benchmark.
Performance of Flagship Ventures Fund Iv-rx, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -43.61 | | | | | |
| Relative Return to S&P 500(%) | -47.57 | | | | | |
Flagship Ventures Fund Iv-rx, L.p. Ownership Network
Ownership Network List of Flagship Ventures Fund Iv-rx, L.p.
Ownership Network Relation of Flagship Ventures Fund Iv-rx, L.p.
Flagship Ventures Fund Iv-rx, L.p. Owned Company Details
What does Moderna Inc do?
Who are the key executives at Moderna Inc?
Flagship Ventures Fund Iv-rx, L.p. is the 10 percent owner of Moderna Inc. Other key executives at Moderna Inc include Chief Financial Officer James M Mock , Chief Legal Officer Shannon Thyme Klinger , and President Stephen Hoge .
Moderna Inc (MRNA) Insider Trades Summary
Over the past 18 months, Flagship Ventures Fund Iv-rx, L.p. made no insider transaction in Moderna Inc (MRNA). Other recent insider transactions involving Moderna Inc (MRNA) include a net sale of 802,832 shares made by Noubar Afeyan , a net sale of 199,941 shares made by Stephen Hoge , and a net sale of 12,167 shares made by Shannon Thyme Klinger .
In summary, during the past 3 months, insiders sold 4,962 shares of Moderna Inc (MRNA) in total and bought 0 shares, with a net sale of 4,962 shares. During the past 18 months, 1,560,701 shares of Moderna Inc (MRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,560,701 shares.
Moderna Inc (MRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Moderna Inc Insider Transactions
Flagship Ventures Fund Iv-rx, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Flagship Ventures Fund Iv-rx, L.p.. You might contact Flagship Ventures Fund Iv-rx, L.p. via mailing address: 55 Cambridge Parkway, 8th Floor, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
